Annovis Bio Announces Pricing of Initial Public Offering
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
BERWYN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a price to the public of $6.00 per share, for gross proceeds of $12,000,000 before deducting underwriting discounts, commissions and offering expenses. In addition, Annovis Bio, Inc. has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of its common stock to cover over-allotments at the initial public offering price less underwriting discount. All of the shares of common stock are being offered by Annovis Bio, Inc. The shares are expected to begin trading on the NYSE American Exchange on January 29, 2020 under the symbol “ANVS.” The offering is expected to close on January 31, 2020, subject to customary closing conditions. ThinkEquity, a division of Fordham Financial
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace [Yahoo! Finance]Yahoo! Finance
- Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s MarketplaceGlobeNewswire
- /C O R R E C T I O N -- Today's Marketplace/PR Newswire
- Annovis to Host Year-End Investor Webcast on December 11, 2024 [Yahoo! Finance]Yahoo! Finance
- Annovis to Host Year-End Investor Webcast on December 11, 2024GlobeNewswire
ANVS
Earnings
- 11/11/24 - Beat
ANVS
Sec Filings
- 12/11/24 - Form 8-K
- 12/11/24 - Form 8-K
- 12/11/24 - Form 424B5
- ANVS's page on the SEC website